The endocrine-disrupting actions of chlorinated aromatic chemicals are well known, and concern has recently heightened because of their ubiquitous presence in the environment and in food (1). Toxicodynamics, i.e., agonist-receptor interactions (2) , play a critical role in endocrine disruption; however, particularly for xenobiotics, which are enzyme inducers and/or yield bioactive (7) . Some monoortho CBs are "mixed" inducers, causing elevation of both EROD and PROD activities (7) . Phase 2 conjugating enzymes are also differentially induced.
Microsomal monooxygenases and phase 2 conjugating enzymes play a pivotal role in PCB toxicoses. Not only are these enzymes differentially induced by different CB congener types, but the CB congeners as well as endogenous hormones are differentially metabolized by the various isozymes (8) . Some hydroxy CB metabolites may have enhanced uterotropic potency (3, 9) . At the same time, other metabolites may inhibit P450 activity in vitro (10) or depress P450 activity in vivo (11, 12) , probably through downregulation of synthesis. The methyl sulfonyl metabolites (which are not generated in tissue culture systems) can also induce P450s (12), but they may inhibit the activity of TCDDinduced P450s in human cell lines (13) .
Therefore, subtle differences in toxicokinetics may be impossible to extrapolate from independent structure-activity relationships, and the net effect of different chemicals on endocrine functions may be even more elusive. The demonstration that two consecutive doses of a specific CB or PCB mixture are more effective than a single larger total dose (5) raises the possibility that the initial dose may induce monooxygenases that enhance the bioactivation of the second dose to a more potent estrogen. On the other hand, if the initial CB merely acts as a priming dose (as with estradiol), the induction of monooxygenases and, especially phase 2 conjugating enzymes, would be expected to attenuate the estrogenic action.
Parallel assessment of estrogenicity and monooxygenase induction might suggest further interactions between biotransformation and endocrine disruption. The prepubertal rat is a sensitive model for estrogenicity if short-term studies, completed before puberty, are required. Acute responses were considered more useful for determining primary actions and interactions because final toxic outcomes after longer dosing and/or observation periods are complicated by endocrine responses to disruption, other repair responses, progression of initial changes to other pathologies, and more complicated toxicokinetics. The sensitivity of the model to estrogenic PCBs is enhanced by dividing the dose over 2 days (5) , but it was unclear how further modifications between weaning and puberty might affect the sensitivity; furthermore, integration of enzyme induction and other toxicokinetic factors into the model required additional time-response considerations.
Materials and Methods
We selected two persistent nonplanar congeners that have different potencies for inducing P4502B1. CB 153 (2,2',4,4',5,5'-hexaCB), recently reported to be estrogenic in the divided-dose protocol (14) , and CB 47 (2,2'4,4'-tetraCB), which was reported to have little estrogenic activity in the single-dose protocol (15) , were compared in 2-day and 5-day dosing regimens. Aroclor 1242, a moderate mixed inducer of monooxygenases (7, 14) , is estrogenic in immature rats in both single-dose and double-dose protocols (2-4;14,15); we used this mixture as a reference toxicant to determine the effect of the 5-day dosing protocol on uterotropic and monooxygenase induction activities.
Female Sprague-Dawley rats nursing litters of 9-11 female pups were purchased from Harlan Sprague-Dawley (Indianapolis, Indiana) and shipped when the litters were 10-15 days of age. At 20 days of age, the pups were weaned, weighed, and separated into dosage groups divided as evenly as possible among litters. Pups were dosed intraperitoneally with PCBs in 0.1 ml corn oil. A positive control (1 pg estradiol in 0.1 ml corn oil) was included from most litters, and a negative control (corn oil alone) was included from all litters. In the 2-day protocol, we dosed pups on days 20 and 21 of age and killed them on day 22; a limited experiment postponed weaning until day 21, and the rats were killed on day 23. In the 5-day protocol pups were dosed on days 23 and 24, days 20, 22, and 24, or days 20, 21, 22, 23, and 24 and killed on day 25. Positive and negative controls received the three-dose treatment protocol.
One day after the last dose, we weighed pups, decapitated them and collected blood from the cervical stump. The reproductive tract was removed and the uterus trimmed of adhering fat and connective tissue and weighed. The liver was perfused in situ with ice-cold Tris-KCl (0.05 M Tris-HCl at pH 7.4 + 0.15 M KCl), removed, weighed, divided into two equal portions and homogenized by hand in Tris-KCl. We resuspended microsomes prepared from the 10-12% homogenates and stored them at -800C until further dilution and assay for protein, EROD, and PROD (14) . For rats killed on day 25, the uteri were homogenized by hand in 1.0 ml Tris buffer and analyzed for protein content.
Blood was allowed to clot, and serum was decanted and stored at -200C until analyzed for PCB residues by hexane-acetone extraction, sodium sulfate dehydration, and GLC (14) . Recoveries bValues are means ± SEM. Data were analyzed by Dunnett's test for multiple comparison in three separate data sets as determined by age at termination. (*, *, t) Significant (p<0.05) difference from corn oil controls in each data set; different symbols indicate significant differences from other treatment groups in the same data set.
CThe large variation was improved by censoring two extreme data points. For n = 3, significant (p<0.05) increases in uterine weight (48.5 ± 1.6) and uterine protein (4.34 ± 0.07) were demonstrated, but the increase in relative uterine weight (0.076 ± 0.02) was not significant with the lower n. (Table 2) .
Residues of the two persistent CBs in the serum were high (up to 22 jig/ml) 1 day after the last of multiple intraperitoneal doses (Table 3) . CB 47 residues were equal the day after two intraperitoneal doses of 30 mg/kg whether the doses were administered on days 20 and 21 or days 21 and 22 (Table 3 ). The serum residues after five daily doses of 30 mg/kg CB 47 were twice that of residues after two daily doses and more variable. Residues were higher in rats with lower total PROD activity (specific activity x mg protein/g liver x g liver) than in rats with greater than twofold higher PROD activity (Fig.  1) . This relationship among individual rats was not apparent after two daily doses. As with CB 47, five daily doses of CB 153 resulted in higher and more variable serum residues than two or three higher doses (Table 3) . Greater total PROD activity also tended to be associated with lower PCB residues in rats given five daily doses of 12 mg/kg CB 153, but the relationship was not as clear as with CB 47 (Fig. 1) ; moreover, in rats administered the higher dose on days 23 and 24, the more likely direct relationship between serum CB and PROD activity is seen (Fig. 2) . Neither pattern was readily discernable in 22-dayold rats or in 25-day-old rats receiving doses on alternate days; nevertheless, differences in PROD induction contributed to the variability of serum residues or vice versa.
Discussion
CBs 47 and 153 are slowly metabolized mainly by PROD and/or other phenobarbital-induced monooxygenases (8) . Small amounts of CB 153 metabolites are transiently (2 hr) present in monkey liver, and much larger amounts persist considerably longer in dog liver (8) . The basal biotransformation potential of the rat is between that of the dog (very high) and the monkey (very low) and can be at least doubled by phenobarbital induction (8) . During the longer exposure (5 days) in the current study, induced PROD as well as induced phase 2 enzymes should be expected to favor lower serum residues of parent compound; however, the apparent rapid decline of PROD activity toward basal levels after relatively recent declines in parent CB requires further explanation. With highly induced PROD, the concentration of metabolites in the liver would be increased; because free hydroxylated CBs have been shown to inhibit some monooxygenase activities (10) , this might explain the more-abrupt-than-expected decrease in measured PROD activity.
In older animals with a larger body fat compartment, CB 153 redistribution to other tissues (rather than metabolism) may be responsible for lower serum residues (16, 17) and limit exposure to hepatic enzymes (17) ; however, in these immature rats with less body fat as well as less time for equilibria to occur, serum residues are relatively predictive of liver residues (Fig. 3) .
The increased inducibility of PROD in 25-day-old rats on the two-dose CB 153 protocol compared to 22-day-old rats introduces greater variability in PROD induction ( Table 2 ). The short-term dosing does not permit stabilization of the high PROD-low serum CB relationship suggested in Figure 1 . In fact, in rats dosed on days 23 and 24, variability is great enough to clearly show the more expected direct relationship (Fig. 2) . This variability is also reflected in the uterotropic effect (Table 1) , but the greatest increase in uterus weight (to 103 mg) was in the rat with the lowest total PROD activity (and lowest serum parent CB level), whereas the rat with the higher serum residues had a uterus that weighed the same as the lower controls (35 mg (14) . with a larger number of animals may be necessary, these large ranges after shorter times in highly induced rats indicate rather steep time-response curves for both toxicokinetics and physiological actions. Increased uterotropic potency from divided doses (5) may be due to induced PROD activity and the generation of more bioactive (9) metabolites in the liver (8) . Phase 2 enzymes such as uridine diphosphate-glucuronyl transferases (Li M-H, Hansen LG, unpublished results) and glutathione transferases (Gillette J, Dauterman WC, personal communication) were also induced in these rats. Therefore, enhanced phase 2 metabolism competes with enhanced bioactivation in an already complex system so that the increased variability observed should have been expected.
When these relationships are considered collectively, it becomes apparent that developmental differences in toxicokinetics and toxicodynamics interact profoundly with dose selection, frequency, and timing so that narrow windows of response are created. If these whole-animal considerations are not fully explored, inaccurate and misleading conclusions may be reached that will seriously impede effective risk assessment.
